Administration of iodinated contrast: What is the risk in cancer patients?

Jose Javier González Cervantes Juan Manuel Mascarós Martínez Estanislao Arana

Published in: European journal of cancer care (2020)

The administration of iodinated contrast in cancer patients was not associated with an increase in kidney outcomes. Risk factors in these patients were age, sex and AH.

Keyphrases

risk factors
end stage renal disease
magnetic resonance
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
contrast enhanced
metabolic syndrome
adipose tissue
computed tomography
insulin resistance